Quercetin greatly improved therapeutic index of doxorubicin against 4T1 breast cancer by its opposing effects on HIF-1α in tumor and normal cells

被引:113
作者
Du, Gangjun [1 ,2 ]
Lin, Haihong [1 ]
Wang, Mei [1 ]
Zhang, Shuo [1 ,2 ]
Wu, Xianchuang [1 ]
Lu, Linlin [1 ]
Ji, Liyan [1 ]
Yu, Lijuan [1 ]
机构
[1] Henan Univ, Pharmaceut Coll, Dept Pharmacol, Kaifeng 475001, Henan, Peoples R China
[2] Chinese Acad Sci, Inst Biophys, Prot & Peptide Pharmaceut Lab, Beijing 100101, Peoples R China
基金
中国国家自然科学基金;
关键词
Quercetin; Doxorubicin; Therapeutic index; HIF-1; alpha; Breast cancer; HYPOXIA-INDUCIBLE-FACTOR-1-ALPHA HIF-1-ALPHA; DNA-DAMAGE; FLAVONOIDS; GROWTH; LINE;
D O I
10.1007/s00280-009-1032-7
中图分类号
R73 [肿瘤学];
学科分类号
100214 [肿瘤学];
摘要
The anthracycline antibiotic doxorubicin (DOX) has been used successfully for treating various types of cancers. However, the therapeutic efficacy of DOX was greatly restricted by its cumulative dose-related cardiotoxicity and common side effects such as bone marrow and immune suppression. Quercetin had better cardioprotective and hepatoprotective activities. The present study was to observe whether quercetin could improve therapeutic index of DOX and explore its mechanisms. Effects of quercetin on doxorubicin (DOX)-induced cytotoxicity were investigated in 4T1 cells and murine spleen cells by methylthiazoletetrazolium assay, flow cytometry and single cell gel electrophoresis. Influences of quercetin on therapeutic efficacy and systemic toxicity of DOX were evaluated in BALB/c mice with 4T1 breast cancer. Hypoxia-inducible factor-1 alpha (HIF-1 alpha) in tumor and normal cells was examined to explore mechanisms of quercetin by Western blot and enzyme-linked immunosorbent assay. In vitro, quercetin at dose less than 100 mu M had only slight effects on cell viability and DOX-induced cytotoxicity in 4T1 cells under normoxia, but it could reverse 4T1 cell resistance to DOX under hypoxia and protect spleen cells against DOX-induced cytotoxicity. In vivo, quercetin suppressed tumor growth and prolonged survival in BALB/c mice bearing 4T1 breast cancer. Importantly, quercetin enhanced therapeutic efficacy of DOX and simultaneously reduced DOX-induced toxic side effects. Further study showed that quercetin suppressed intratumoral HIF-1 alpha in a hypoxia-dependent way but increased its accumulation in normal cells. HIF-1 alpha siRNA abolished effects of quercetin on both tumor and normal cells. These results suggested that quercetin could improve therapeutic index of DOX by its opposing effects on HIF-1 alpha in tumor and normal cells, and was a promising candidate as anticancer agents.
引用
收藏
页码:277 / 287
页数:11
相关论文
共 31 条
[1]
Abe O, 2005, LANCET, V366, P2087, DOI 10.1016/s0140-6736(05)66544-0
[2]
Quercetin induces apoptosis via caspase activation, regulation of Bcl-2, and inhibition of PI-3-kinase/Akt and ERK pathways in a human hepatoma cell line (HepG2) [J].
Belen Granado-Serrano, Ana ;
Angeles Martin, Maria ;
Bravo, Laura ;
Goya, Luis ;
Ramos, Sonia .
JOURNAL OF NUTRITION, 2006, 136 (11) :2715-2721
[3]
Benavente-García O, 2007, CURR CANCER DRUG TAR, V7, P795
[4]
The quercetin paradox [J].
Boots, Agnes W. ;
Li, Hui ;
Schins, Roel P. F. ;
Duffin, Rodger ;
Heemskerk, Johan W. M. ;
Bast, Aalt ;
Haenen, Guido R. M. M. .
TOXICOLOGY AND APPLIED PHARMACOLOGY, 2007, 222 (01) :89-96
[5]
Choi HJ, 2006, MOL CELLS, V22, P291
[6]
Collins Andrew R, 2004, Mol Biotechnol, V26, P249
[7]
Genistein and quercetin increase connexin43 and suppress growth of breast cancer cells [J].
Conklin, Chris M. J. ;
Bechberger, John F. ;
MacFabe, Derrick ;
Guthrie, Najla ;
Kurowska, Elzbieta M. ;
Naus, Christian C. .
CARCINOGENESIS, 2007, 28 (01) :93-100
[8]
Damianaki A, 2000, J CELL BIOCHEM, V78, P429, DOI 10.1002/1097-4644(20000901)78:3<429::AID-JCB8>3.0.CO
[9]
2-M
[10]
Quercetin and myricetin protect against hydrogen peroxide-induced DNA damage (strand breaks and oxidised pyrimidines) in human lymphocytes [J].
Duthie, SJ ;
Collins, AR ;
Duthie, GG ;
Dodson, VL .
MUTATION RESEARCH-GENETIC TOXICOLOGY AND ENVIRONMENTAL MUTAGENESIS, 1997, 393 (03) :223-231